Radiotherapy & Oncology
Volume 96, Issue 1 , Pages 13-18 , July 2010

Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial

  • Abrahim Al-Mamgani

      Affiliations

    • Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Address: Department of Radiation Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands.
    • ,
  • Wilma D. Heemsbergen

      Affiliations

    • The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    • ,
  • Peter C. Levendag

      Affiliations

    • Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    • ,
  • Joos V. Lebesque

      Affiliations

    • The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

Received 24 February 2009 ,Revised 19 February 2010 ,Accepted 23 February 2010.

References 

  1. Al-Mamgani A, van Putten WLJ, Heemsbergen WD, et al. Update of the Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72:980–988
  2. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74
  3. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233–1239For an important correction: Zietman AL. Correction: inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate. JAMA. 2008;299:898–900
  4. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8:475–487
  5. Peeters STH, Heemsbergen WD, Koper PCM, et al. Dose–response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24:1990–1996
  6. Stephenson RA. Prostate cancer trends in the era of prostate-specific antigen: an update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am. 2002;29:173–181
  7. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110–114
  8. Bos LJ, Damen EMF, de Boer RW, et al. Reduction of rectal dose by integration of the boost in the large-field treatment plan for prostate irradiation. Int J Radiat Oncol Biol Phys. 2002;52:254–265
  9. Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:380–385
  10. Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys. 2008;71:1028–1033
  11. Cheung R, Tucker SL, Lee AK, et al. Dose–response characteristics of low- and intermediate-risk prostate cancer treated with external bean radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61:993–1002
  12. Roach M III, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer. Recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  13. Kuban DA, Thames HD, Levy LB, et al. Long-term multi-institutional analysis of stage T1–T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003;57:915–928
  14. De Meerleer GO, Fonteyne VH, Vakaet L, et al. Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control. Radiother Oncol. 2007;82:16–166
  15. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103–108
  16. Zapatero A, Valcarcel F, Calvo FA, et al. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol. 2005;23:6561–6568
  17. Pinover MV, Hanlon AL, Horwitz EM, Hanks GE. Defining the appropriate radiation dose for pretreatment PSA<or=10ng/ml prostate cancer. Int J Radiat Oncol Biol Phys. 2000;47:649–654

PII: S0167-8140(10)00127-1

doi: 10.1016/j.radonc.2010.02.022

Radiotherapy & Oncology
Volume 96, Issue 1 , Pages 13-18 , July 2010

Article Tools

* Image Usage & Resolution